HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tariff Hikes On Chinese Imports Still In Play As US Plans December Increase

Executive Summary

Trump administration negotiations with China representatives led to US suspending tariff increase to 25% on product categories announced set to begin 15 October. But 15% tariff added in September on about $112bn worth of Chinese goods remains and US still plans in December to impose separate 10% tariff hike on $160bn in other products.

You may also be interested in...



Essential Oils Off EU Imports Tariff List In Trade War Win For Fragrance Creators

Essential oils no longer on list of products slated for EU tariff increases effective 18 October, a win for US fragrance industry facing uncertainty in tumultuous global trade climate. Fragrancy industry, like dietary supplement manufacturers, still face higher tariffs on imports from China as next round of hikes is scheduled to start 15 October.

Full Plate Of Dietary Ingredients In Latest US Tariff Hikes On Chinese Imports

Consumer health industry groups plan to comment at June 17 public hearing on USTR plan for 25% tariff on imports from China not included in three earlier rounds of duties. NPA applauds USTR for allowing exclusion process for imported products valued at $200bn already hit with tariffs in 2018.

FDA Action Items For CBD Policy? The List Is Short Due To 'Critical' Data Gaps

FDA has little in the way of good information it can list on its CBD policy agenda so far, says Principal Deputy Commissioner Amy Abernethy. At recent regulatory conference, she said, "Like it or not, there is a massive human experiment going on right now. There’s CBD in most different product categories and people of many different backgrounds with potential vulnerabilities taking CBD."

Topics

UsernamePublicRestriction

Register

RS149310

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel